On May 22, Impact Therapeutics-B (07630.HK) rose 13.17% in regular trading, trading at HK$35.68 per share, with trading volume of approximately HK$8.79 million. The stock staged a strong rebound following several sessions of profit-taking pressure since its IPO debut.

The company listed on the Hong Kong Stock Exchange on May 13 at an IPO price of HK$20.10 per share, with its public offering oversubscribed by 2,282 times. Shares surged 108.26% on the first trading day, closing at HK$41.86. After sustaining elevated levels for multiple sessions, the stock retreated more than 15% from its post-listing high, with a decline exceeding 5% recorded on May 21 as short-term profit-taking intensified. Today's rebound suggests capital is flowing back in following the correction.

Impact Therapeutics is a commercial-stage biotech company focused on precision anti-cancer therapies based on synthetic lethality mechanisms. Its core product senaparib, a PARP1/2 inhibitor, was approved in January for first-line maintenance treatment of ovarian cancer in China and was included in the National Medical Insurance Directory in December, with reimbursed pricing effective since January. The company remains in a loss-making stage, reporting a net loss of approximately RMB 296 million against revenue of RMB 38.25 million.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)